A Randomised Phase II Study of Sunitinib versus Dacarbazine in the Treatment of Patients with Metastatic Uveal Melanoma

Trial Profile

A Randomised Phase II Study of Sunitinib versus Dacarbazine in the Treatment of Patients with Metastatic Uveal Melanoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jul 2016

At a glance

  • Drugs Sunitinib (Primary) ; Dacarbazine
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms SUAVE
  • Most Recent Events

    • 25 Jul 2016 Planned End Date changed from 1 Aug 2016 to 1 Nov 2016.
    • 25 Jul 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Sep 2016.
    • 26 Jan 2016 Planned End Date changed from 1 Apr 2014 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top